Nanosynth disposes of Gyrometric and Cloudveil as part of refocussed strategy

Nanosynth Group plc (LON:NNN) has announced that it has agreed to return control of Cloudveil Limited, a wholly owned subsidiary of the Company, to Cloudveil’s founder, Antony Hugo Gillum-Webb, by transferring the Company’s shares in Cloudveil to the Founder for nominal consideration, effective immediately.

The Disposal is in line with the Board’s strategy which is to focus on the synthesis and application of the Company’s core capabilities and has been strengthened by the appointment of Mark Duffin as CEO in September 2021. The Disposal follows the Board’s decision earlier this year to reduce its holding in Gyrometric Systems Limited, as approved by shareholders in August 2021, and following this the Group will have two wholly owned subsidiaries, being Pharm 2 Farm Ltd and nanosynth Ltd.

The Board also announces that following the Gyrometric transaction, John Richardson has resigned from the Board as an executive director, effective immediately, to focus on product management activities within P2F, the Company’s main subsidiary.

Antony Hugo Gillum-Webb is also a director of Cloudveil and as a result, the Disposal is considered to be a related party transaction in accordance with Rule 13 of the AIM Rules for Companies. Accordingly, the Directors of nanosynth, being Mark Duffin, Antony Legge, Richard Clarke, Dr Felicity Sartain and Dr Gareth Cave, having consulted with the Company’s nominated adviser, SP Angel Corporate Finance LLP, consider that the terms of the Disposal are fair and reasonable insofar as the Company’s shareholders are concerned.

Antony Legge, Chairman of nanosynth, said: “The disposals of Gyrometric and Cloudveil are the last steps in our refocussing strategy. With the opportunities available to us, it is vital our management and financial resources are concentrated on realising returns for shareholders by exploiting our strong position within the nano-particle sector.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Nanosynth Group plc

    More articles like this

    Nanosynth Group plc

    Nanotechnology in cosmetics and cosmeceuticals

    Nanoparticles (NPs) are defined as materials with dimensions smaller than 100 nm and presenting various shapes, i.e., spheres, rods, dendritic shapes, etc. This definition is accepted by the European Union (EU) Commission. It should be noted, however,

    Nanosynth Group plc

    Nanoparticles in cosmetics

    Nanoparticles are particles that are smaller than 100 nanometer (1/10,000 millimeter) which is about 40,000 times thinner than a hair. There are two forms of nanoparticles: soluble and biodegradable nanoemulsions such as liposomes and insoluble nanopigments

    Nanosynth Group plc

    What nanoparticles do to our cells

    During the past few years, nanoparticles have been increasingly present in our everyday lives. To gain a better understanding of their health impacts, several studies have focused on the effects they have on our bodies and

    Nanosynth Group plc

    Role of nanotechnology for design and development of cosmeceutical

    Nanotechnology is an innovative area of science that includes the design, characterization, production, and application of materials, devices and systems by controlling shape and size at the nanometer scale (1–100 nm). Nanotechnology incorporation in cosmetic formulation

    Nanosynth Group plc

    Nanotech could be the next frontier of drug delivery

    Nanotechnology is an emerging and rapidly developing area in the pharmaceutical and medicinal field. For example, nanoparticles can be used as drug delivery systems. Nanotechnology could help overcome the limitations of conventional drug delivery such as biodistribution and

    Nanosynth Group plc

    Nanoparticles to aid cancer treatments

    Conventional therapies in cancer treatment face challenges in delivery of drugs in the body and just the quantity needed, due to the toxic nature of the medicines used that have unwanted side effects. Nanomaterials have ‘enormous’

    Nanosynth Group plc

    Nanoparticles: Emerging trends in human health and environment

    As part of the ongoing Govt of India initiative “Azadi ka Amrit Mahatosav”, the Indian Journal of Biochemistry and Biophysics (IJBB), CSIR-National Institute of Science Communication and Policy Research (NIScPR), New Delhi, has brought out its

    Nanosynth Group plc

    Nanoparticles that self-assemble inside cells to fight cancer

    Inspired by viral replication, researchers developed a therapy that commandeers biological processes to craft nanoparticles within macrophages to aid in cancer therapy. Through self-assembly, the nanoparticles address some of the delivery issues plaguing present renditions of nanomedicines,

    Nanosynth Group plc

    nanosynth Group getting a huge amount of traction (LON:NNN)

    nanosynth’s Mark Duffin discusses what the company does, the Volz trial results, joint venture with a global wellness company and what investors can expect for the rest of the year in this exclusive interview with DirectorsTalk.

    Nanosynth Group plc

    Nanotechnology in the nutricosmetics industry

    Nanotechnology for Nutricosmetics Nanocarriers are ubiquitous within nanomedicine; however, with skin quality and health in high demand for consumers, these fields have overlapped. The use of nanotechnology and nanoformulations as delivery systems for improving the performance

    Nanosynth Group plc

    Nanotechnology in cosmetics

    Nanotechnology is the science of manipulating atoms and molecules in the nanoscale – 80,000 times smaller than the width of a human hair. The world market for products that contain nanomaterials is expected to reach $2.6